The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
But acquisition charges drag earnings into loss
The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
The agreement could rise to $900 million if key commercial milestones are met
The Danish biotech company confirmed the global study will begin in the second half of 2026
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
Subscribe To Our Newsletter & Stay Updated
